ATE215946T1 - Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf) - Google Patents

Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)

Info

Publication number
ATE215946T1
ATE215946T1 AT96939208T AT96939208T ATE215946T1 AT E215946 T1 ATE215946 T1 AT E215946T1 AT 96939208 T AT96939208 T AT 96939208T AT 96939208 T AT96939208 T AT 96939208T AT E215946 T1 ATE215946 T1 AT E215946T1
Authority
AT
Austria
Prior art keywords
necrosis factor
mmp
tnf
inhibitors
tumor necrosis
Prior art date
Application number
AT96939208T
Other languages
German (de)
English (en)
Inventor
Andrew Douglas Baxter
John Gary Montana
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9523828.3A external-priority patent/GB9523828D0/en
Priority claimed from GBGB9607121.2A external-priority patent/GB9607121D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ATE215946T1 publication Critical patent/ATE215946T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT96939208T 1995-11-22 1996-11-22 Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf) ATE215946T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9523828.3A GB9523828D0 (en) 1995-11-22 1995-11-22 Compounds
GBGB9607121.2A GB9607121D0 (en) 1996-04-04 1996-04-04 Compounds
PCT/GB1996/002892 WO1997019075A1 (en) 1995-11-22 1996-11-22 Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)

Publications (1)

Publication Number Publication Date
ATE215946T1 true ATE215946T1 (de) 2002-04-15

Family

ID=26308152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96939208T ATE215946T1 (de) 1995-11-22 1996-11-22 Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)

Country Status (19)

Country Link
US (1) US6048841A (enExample)
EP (1) EP0874842B1 (enExample)
JP (1) JP2000500482A (enExample)
KR (1) KR19990067687A (enExample)
CN (1) CN1072667C (enExample)
AT (1) ATE215946T1 (enExample)
AU (1) AU711907B2 (enExample)
BR (1) BR9611636A (enExample)
CA (1) CA2229438C (enExample)
CZ (1) CZ291337B6 (enExample)
DE (1) DE69620639T2 (enExample)
ES (1) ES2172690T3 (enExample)
HU (1) HUP9904131A3 (enExample)
IL (1) IL123431A (enExample)
MX (1) MX9804052A (enExample)
NO (1) NO982290L (enExample)
NZ (1) NZ322565A (enExample)
PL (1) PL326710A1 (enExample)
WO (1) WO1997019075A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
RU2201931C2 (ru) 1996-11-20 2003-04-10 Биомежер Инкорпорэйтед Ингибиторы фарнезилтрансферазы и способы ингибирования фарнезилтрансферазы
CA2408408C (en) 2000-05-12 2013-07-09 Genzyme Corporation Modulators of tnf- alpha signaling
EP1282614B1 (en) 2000-05-15 2003-11-12 Darwin Discovery Limited Hydroxamic acid derivatives
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
DE60305446T4 (de) * 2002-01-07 2009-07-09 Eisai R&D Management Co., Ltd. Desazapurine und deren verwendung
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
DE60335652D1 (de) * 2002-11-21 2011-02-17 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
US20040259744A1 (en) * 2003-12-19 2004-12-23 Meidong Yang Skin and hair cleansers containing sulfur
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
PL227790B1 (pl) 2015-08-13 2018-01-31 Slaski Univ Medyczny W Katowicach Fosfoniany acetylenowych pochodnych betuliny o działaniu przeciwnowotworowym, sposób ich wytwarzania i zastosowanie.
CN120617250A (zh) * 2025-07-04 2025-09-12 南京农业大学 小分子化合物Nec-1s在制备治疗脑膜炎药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525629A (en) * 1992-04-07 1996-06-11 British Bio-Technology Limited Inhibition of cytokine production
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
JP3787605B2 (ja) * 1994-10-05 2006-06-21 ダーウィン・ディスカバリー・リミテッド ペプチジル化合物および金属プロテアーゼのインヒビターとしてのその治療的使用

Also Published As

Publication number Publication date
CA2229438A1 (en) 1997-05-29
AU711907B2 (en) 1999-10-21
BR9611636A (pt) 1999-12-28
IL123431A0 (en) 1998-09-24
ES2172690T3 (es) 2002-10-01
CN1072667C (zh) 2001-10-10
JP2000500482A (ja) 2000-01-18
IL123431A (en) 2001-05-20
DE69620639T2 (de) 2002-10-17
EP0874842A1 (en) 1998-11-04
CN1202895A (zh) 1998-12-23
HUP9904131A2 (hu) 2000-06-28
AU7634396A (en) 1997-06-11
MX9804052A (es) 1998-09-30
NO982290D0 (no) 1998-05-20
WO1997019075A1 (en) 1997-05-29
HUP9904131A3 (en) 2002-04-29
CZ145598A3 (cs) 1998-08-12
KR19990067687A (ko) 1999-08-25
PL326710A1 (en) 1998-10-26
NO982290L (no) 1998-05-20
US6048841A (en) 2000-04-11
CZ291337B6 (cs) 2003-02-12
DE69620639D1 (de) 2002-05-16
EP0874842B1 (en) 2002-04-10
CA2229438C (en) 2006-01-17
NZ322565A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
DE69620639D1 (de) Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)
ATE188969T1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
PL319503A1 (en) Peptide compounds and their therapeutic application as inhibitors
ATE266000T1 (de) Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
DE69628019D1 (de) Chinolone und deren therapeutische verwendung
DE69835518D1 (de) Imidazolyl-cyclische acetale
DE69722656D1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
DE69836563D1 (de) INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYLSUBSTITUIERTEN HARNSTOFFEN
FI980038L (fi) Tuumorinekroositekijän alfa inhibiittoreita
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
BG104996A (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
IL122782A (en) Triazole salts and pharmaceutical compositions containing the same and methods for evaluating the susceptibility of a cancer to growth inhibition utilizing the same
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
ATE292626T1 (de) Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf)
BG103832A (en) Leptin as tumour cells proliferation inhibitor
ES2000734A6 (es) Un procedimiento para la preparacion de pirimidinas
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
ATE174219T1 (de) Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
DK1051395T3 (da) N-hydroxyformamidderivater
ATE229034T1 (de) 3-mercaptoacetylamino-1,5-substituierte-2-oxo- azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen
ATE352306T1 (de) Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
ATE358673T1 (de) Nf-kb-inhibitoren
WO2005046658A3 (en) Methods of modulating angiogenesis and cancer cell proliferation
HK1012191A (en) Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)
ATE215935T1 (de) Heterozyklische verbidungen mit mmp und tnf inhibitorisher wirkung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties